We are live on ! Find out more
RCKT icon

Rocket Pharmaceuticals
RCKT

178 hedge funds and large institutions have $1.96B invested in Rocket Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 74 increasing their positions, 50 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more call options, than puts

Call options by funds: $5.17M | Put options by funds: $3.15M

48% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 50

1.56% less ownership

Funds ownership: 102.06% → 100.51% (-1.6%)

4% less funds holding

Funds holding: 186 → 178 (-8)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

21% less capital invested

Capital invested by funds: $2.48B → $1.96B (-$522M)

22% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 27

Holders
178
Holders Change
-8
Holders Change %
-4.3%
% of All Funds
2.57%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.06%
New
21
Increased
74
Reduced
50
Closed
27
Calls
$5.17M
Puts
$3.15M
Net Calls
+$2.02M
Net Calls Change
-$15.1M

Top Buyers

1
WP
Woodline Partners
California
+$12.9M
2
EC
EcoR1 Capital
California
+$11.7M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$10.1M
4
Citadel Advisors
Citadel Advisors
Florida
+$8M
5
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$7.9M

Top Sellers

1
ACA
Avoro Capital Advisors
New York
-$34M
2
State Street
State Street
Massachusetts
-$32.5M
3
LGM
Logos Global Management
California
-$21.8M
4
PA
Perceptive Advisors
New York
-$12.7M
5
CAM
Cormorant Asset Management
Massachusetts
-$8.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
1
RTW Investments
New York
$381M – – –
Wellington Management Group
2
Wellington Management Group
Massachusetts
$197M -$8.71K -379 -0%
BlackRock
3
BlackRock
New York
$133M +$6.03M +262,717 +4%
Vanguard Group
4
Vanguard Group
Pennsylvania
$125M +$10.1M +437,665 +8%
Westfield Capital Management
5
Westfield Capital Management
Massachusetts
$93.2M +$7.9M +343,892 +9%
MC
6
Maverick Capital
Texas
$84.6M +$919K +40,000 +1%
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
$68.2M +$5.2M +226,288 +8%
Janus Henderson Group
8
Janus Henderson Group
United Kingdom
$62.8M +$7.19M +313,062 +12%
Citadel Advisors
9
Citadel Advisors
Florida
$60.7M +$8M +348,256 +14%
State Street
10
State Street
Massachusetts
$59.9M -$32.5M -1,413,211 -34%
Franklin Resources
11
Franklin Resources
California
$40.3M +$146K +6,360 +0.3%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$34.5M +$2.32M +101,023 +7%
FLSM
13
Frazier Life Sciences Management
California
$33.6M – – –
BC
14
Boxer Capital
California
$31.6M – – –
PA
15
Perceptive Advisors
New York
$26.8M -$12.7M -554,471 -31%
Bank of America
16
Bank of America
North Carolina
$26.7M +$5.04M +219,556 +22%
Pictet Asset Management
17
Pictet Asset Management
Switzerland
$26.4M -$2.23M -97,060 -7%
CAC
18
Cowen and Company
New York
$23.7M – – –
NHAS
19
Novo Holdings A/S
Denmark
$23.7M +$1.15M +50,000 +5%
APM
20
Avidity Partners Management
Texas
$23.7M +$1.72M +75,000 +7%
BAMCO Inc
21
BAMCO Inc
New York
$21.1M -$258K -11,213 -1%
Dimensional Fund Advisors
22
Dimensional Fund Advisors
Texas
$20.4M -$1.92M -83,613 -8%
EAM
23
Eventide Asset Management
Massachusetts
$16.6M +$6.43M +279,959 +57%
TCM
24
Tang Capital Management
California
$16.1M +$2.07M +90,000 +14%
Goldman Sachs
25
Goldman Sachs
New York
$15M +$6.09M +265,033 +62%
1
2 3 4 5

RCKT Hedge Fund Activity: Q2 2024 in Review

178 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q2 2024, worth a combined $1.96B — down 21% from $2.48B a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of RCKT and 21 opened new positions — a net loss of 6 holders — while 50 trimmed existing stakes and 74 added.

The largest buyer was Woodline Partners, opening a new position worth an estimated $12.9M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $34M sold.

  • 178 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q2 2024, down from 186 in Q1 2024.
  • Funds reported $1.96B of Rocket Pharmaceuticals stock for Q2 2024, down 21% quarter-over-quarter.
  • 21 funds opened new Rocket Pharmaceuticals positions in Q2 2024 and 27 closed out, a net change of -6 holders.
  • The largest Rocket Pharmaceuticals buyer in Q2 2024 was Woodline Partners, an estimated $12.9M added.
  • The largest Rocket Pharmaceuticals seller in Q2 2024 was Avoro Capital Advisors, an estimated $34M sold.

Based on aggregated 13F filings for Q2 2024.